Company news
Adicet Bio, Inc. (NASDAQ:ACET) news
Adicet Bio, Inc. news releases on 6ix. Latest, Sep 28, 2026: Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study…
Press releases & updates
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
September 28, 2026
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
September 25, 2026
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
September 1, 2026
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
August 27, 2026
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
July 21, 2026
Adicet Bio : Amendment to Annual Report (Form 10-K/A)
May 20, 2026
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 14, 2026
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
May 13, 2026
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
March 12, 2026
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
January 30, 2026
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
January 7, 2026
Adicet Bio Announces Reverse Stock Split
December 26, 2025
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 28, 2025
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 5, 2025
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
October 28, 2025
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
October 16, 2025
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis and Systemic Lupus Erythematosus
October 8, 2025
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
October 7, 2025
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
October 7, 2025
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 6, 2025
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
August 5, 2025
MaxCyte Signs Platform License Agreement with Adicet Bio
August 4, 2025
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
July 24, 2025
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
May 21, 2025
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 6, 2025
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
April 30, 2025
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
April 28, 2025
Adicet Bio Appoints Michael Grissinger to the Board of Directors
April 17, 2025
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
March 31, 2025
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
March 6, 2025
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
March 3, 2025
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
February 27, 2025
Adicet Announces Completion of Merger with resTORbio
September 14, 2020
Adicet Bio Receives $10 Million Product Development Milestone From Regeneron
August 4, 2020